CJC-1295 vs Sermorelin

What is the difference between CJC-1295 and sermorelin?

In a CJC-1295 vs sermorelin comparison, both are synthetic growth-hormone-releasing hormone (GHRH) analogs, but CJC-1295 is engineered to last far longer in the body than sermorelin.

Sermorelin is a shortened GHRH fragment (the first 29 amino acids of natural GHRH). It binds the GHRH receptor on the pituitary and prompts a natural pulse of GH, then clears quickly (Prakash and Goa, 1999).

CJC-1295 is also a modified GHRH(1-29) sequence, but the version studied with drug affinity complex (DAC) adds a chemical group that binds to albumin in blood. That binding protects the molecule from breakdown and stretches its action out over days rather than minutes (Teichman et al., 2006). A version without DAC also exists in research settings and behaves with a much shorter duration closer to plain GHRH analogs.

The practical takeaway: same receptor target, very different clock.

How long does each one last (half-life)?

Sermorelin clears in minutes; CJC-1295 with DAC keeps GH and IGF-1 raised for days.

In the trial by Teichman et al. (2006), a single dose of CJC-1295 with DAC produced sustained increases in GH and IGF-1 for up to about 6 days, and repeated weekly or twice-weekly dosing kept IGF-1 raised. By contrast, Prakash and Goa (1999) report sermorelin's plasma half-life at roughly 11 to 12 minutes, consistent with its role as a short, pulse-triggering agent. That same 11 to 12 minute figure appears independently in the sermorelin acetate (Geref) prescribing information, which reports a half-life of 11 to 12 minutes after intravenous or subcutaneous administration, so the number does not rest on a single review.

How do GH and IGF-1 respond to each?

Sermorelin produces short GH spikes that mimic natural pulses; CJC-1295 with DAC produces a longer, flatter rise in both GH and IGF-1.

Because sermorelin clears in minutes, the GH it triggers rises and falls in a pattern closer to the body's own episodic pulses (Prakash and Goa, 1999). IGF-1, which is downstream of GH and made largely in the liver, follows those pulses more loosely.

CJC-1295 with DAC changes the shape of that response. In the trial by Teichman et al. (2006), participants showed dose-dependent increases in mean GH concentrations and sustained IGF-1 elevation across days, not minutes. The trade-off researchers describe is physiological pattern: pulsatile signaling versus continuous signaling. Which pattern matters for a given research question is exactly the kind of thing a qualified clinician or study protocol defines.

For broader context on how GH secretagogues differ from other classes, see how ipamorelin acts as a selective GH secretagogue (Raun et al., 1998) and how the oral agent MK-677 raised fasting glucose and lowered insulin sensitivity in older adults (Nass et al., 2008). Those are separate compounds, but they frame why "raises GH" is not one single effect.

What dosing has research reported?

This section describes what published studies administered to participants. It is not a recommendation, and it is not a protocol for any individual.

In the CJC-1295 study, Teichman et al. (2006) administered single and multiple subcutaneous doses in the microgram-per-kilogram range and reported the sustained GH/IGF-1 elevations noted above. Sermorelin has a long clinical history as a GHRH analog used in research and diagnostic settings, and Prakash and Goa (1999) review its pharmacology, including its very short half-life that shapes how it was studied.

Any personal dose, schedule, or route is a clinical decision. This page does not provide that. Route it to a qualified clinician.

What are the side-effect profiles?

Both are GHRH analogs, and the most commonly described effects in the literature relate to injection-site reactions and GH-axis physiology.

Prakash and Goa (1999) describe sermorelin's profile as generally consistent with a short-acting GHRH agent, with local injection-site responses among the reported effects. For CJC-1295 with DAC, Teichman et al. (2006) reported that the compound was tolerated across the doses studied while producing sustained GH/IGF-1 rises. Because any agent that raises GH and IGF-1 can influence glucose handling, the class context matters: raising GH signaling has been linked to reduced insulin sensitivity in a related secretagogue (Nass et al., 2008). Long-term human safety data specific to these two compounds is limited, and that limit should be stated plainly in any research plan.

Which one should a researcher consider?

There is no universal winner; the choice tracks the research question about GH signaling pattern and duration.

If the question centers on short, pulse-like GH release that mirrors natural episodic secretion, sermorelin's very short half-life is the defining feature (Prakash and Goa, 1999). If the question centers on sustained GH and IGF-1 elevation from infrequent dosing, CJC-1295 with DAC's multi-day action is the defining feature (Teichman et al., 2006). Both depend on a working pituitary, so neither is a GH replacement. The decision, and any protocol built on it, belongs with a qualified clinician or an approved study design.